Windtree Therapeutics INC /DE/ 10-Q quarterly reports

Windtree Therapeutics reported a significant net loss of $42.8 million for the nine months ended September 30, 2025, alongside a Nasdaq delisting and substantial doubt about its ability to continue as a going concern.

Windtree Therapeutics reported significant losses and a going concern warning, while announcing a new strategy to acquire revenue-generating products and launch a crypto treasury strategy.

Windtree Therapeutics reports a net loss of $4.0 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also pursuing a new revenue-generating acquisition strategy.

Windtree Therapeutics' Q3 2024 report details a net loss of $2.7 million, significant financial restructuring, and positive clinical trial results for istaroxime.

Windtree Therapeutics reports a net loss of $1.8 million for the six months ended June 30, 2024, while securing new financing to extend operations into October 2024.

Windtree Therapeutics reported a net income of $10.2 million for Q1 2024, primarily driven by a significant gain on debt extinguishment, while also highlighting ongoing clinical development efforts.